Bone Morphogenetic Protein 6 Expression in Oral Cavity Squamous Cell Cancer is Associated With Bone Invasion

Alexandra E. Kejner, MD; M. Benjamin Burch, MS; Larissa Sweeny, MD; Eben L. Rosenthal, MD

Objectives/Hypothesis: To evaluate bone invasion, survival, and expression of bone morphogenetic protein-6 (BMP-6) in oral cavity cancer in the context of known biomarkers indicative of poor prognosis.

Study Design: Molecular expression study combined with retrospective chart review of corresponding patients at a tertiary care center.

Methods: Between 2000 and 2009, a total of 197 patients underwent resection for oral cavity squamous cell carcinoma. Of these, 30 pathologic specimens were chosen for further molecular analysis. These 30 patients were separated into three groups (10 per group) based on American Joint Committee on Cancer (AJCC) staging and staging based on size alone (T staging/size).

The first group consisted of tumors staged as T2/2 based on size less than 4 cm and that had no evidence of bone invasion. The T2/4 group consisted of tumors that were upstaged from T2 based on bone invasion. The T4/4 group consisted of tumors that were large with and without bone invasion. The expression of extracellular matrix metalloproteinase inducer (EMMPRIN), BMP-6, and epidermal growth factor receptor (EGFR) was examined using immunohistochemistry techniques. Patient demographics, tumor characteristics, survival, and recurrence were compared.

Results: Average follow-up was 21 months. Expression of BMP-6 was significantly higher in the T2/4 cohort (tumor less than 4 cm with bony invasion) than the larger tumors without bone invasion (T4/4 cohort, P = .05). In addition, increased BMP-6 expression correlated with aggressive behavior in the smaller tumors. Furthermore, increased EGFR expression positively correlated with increased levels of BMP-6.

Conclusions: Increased expression of BMP-6 in oral cavity cancer may affect bone invasion.

Key Words: Head and neck, bone morphogenetic protein-6, immunohistochemistry, tumor biomarkers, oral cavity cancer; squamous cell carcinoma.

Level of Evidence: N/A.

INTRODUCTION

Oral cavity squamous cell carcinoma (OCSCC) represents a significant therapeutic challenge because of its aggressive local and regional behavior. Surgical resection is often the mainstay of therapy, but advanced-stage disease often requires adjuvant medical therapy, compounding the deficits associated with surgery. This can result in poor functional outcomes for this patient population, including xerostomia, mucositis, osteoradionecrosis, ulceration, dysphagia, aspiration, and need for other surgery. Predictors for requiring adjuvant therapy are critical to ensure the appropriate treatment plan and duration. OCSCC with bone invasion often portends a poor prognosis as well as confers a need for additional therapy.

Interestingly, patients with similar T classification based on size can have substantially different prognosis based on the presence of bone invasion. Although this has been well recognized to carry a poor prognosis in the literature, the underlying biology of this relationship remains largely unknown. It is thought that this may be related to surgical margins, implications of the size of tumor, and access to bone marrow. Ebrahimi et al. showed that patients with medullary invasion of the mandible did not experience a locoregional recurrence but rather distant metastases (which is often predictive of worsened survival). Access to the cancellous bone of the mandible may grant these tumors a mode of hematogenous spread or alternatively could signify that these tumors are more aggressive in general.

Investigations into biomarkers predictive of bone invasion have included circulating C-reactive protein, vascular endothelial growth factor, epidermal growth factor receptor (EGFR), and extracellular matrix metalloproteinase inducer (EMMPRIN). Despite its known relationship to bone remodeling and its expression in cancer, the role of bone morphogenetic protein-6 (BMP-6) has not been evaluated in oral cavity cancer. It has, however, been demonstrated to be upregulated in esophageal cancer. Furthermore, expression of several members of the BMP family has been shown to induce ectopic bone formation in vivo in breast and prostate cancers. In particular, bone invasion in the presence of
increased BMP-6 expression has been extensively documented in breast and prostate.\textsuperscript{11–14} To investigate the potential role of BMP-6 in oral cavity tumors, we evaluated 30 patients with tumors of comparable size and compared molecular expression of BMP-6 in those tumors with and without mandibular invasion. To provide a comparison of well-known biomarkers of aggressive behavior in OSCC, BMP-6 was evaluated in conjunction with EMMPRIN and EGFR.

**MATERIALS AND METHODS**

**Patient Population**

Tumor specimens were collected from 197 patients with OCSCC between 2000 and 2009. At random, 30 patient specimens were chosen from this group based on their American Joint Committee on Cancer staging (AJCC) and a classification criteria based on size alone (TAJCC/SIZE). Given the large span of time from which these patients were pulled, the AJCC classifications are congruent with the most recent edition at the time of diagnosis. The T-classification criterion based on size was defined by lesion length: T2 represents small tumors, less than 4 cm that did not have bone invasion, both with and without bone invasion, and T4 consisted tumors larger than or equal to 4 cm also with or without bone invasion. Demographics were compared across the groups including age, sex, and race. Tumor and disease characteristics were also evaluated including bone invasion, perineural invasion, presence of metastatic disease, margin status after definitive resection, and recurrence. Immunohistochemistry was performed to assess presence and upregulation of biomarkers including BMP-6, EGFR, and EMMPRIN as well as to assess whether there were any relationships between these biomarkers.

**Immunohistochemistry**

Embedded paraffin slides containing patient tumor tissue were obtained from the University of Alabama–Birmingham Department of Surgical Pathology. Slides were incubated at 60°C for 1 hour. Slides were then immersed in EZ-DEWAX solution (Biogenex Laboratories, San Ramon, CA) for 5 minutes with occasional agitation, then transferred to a fresh container of EZ-DEWAX for an additional 5 minutes. Antigen retrieval was performed using a 1:100 solution of citrate buffer (Fisher Scientific TA-050-CBX, Logan, UT) and incubated at 90°C for 10 minutes. Slides were rinsed with deionized distilled water for 5 minutes, then blocked with a 5% (wt/vol) solution of bovine serum albumin in TBST buffer for 5 minutes at room temperature. Excess blocking solution was removed from the slides, and samples were then incubated with primary antibody in a humidified chamber at room temperature for 1 hour. Following hybridization, the slides were rinsed once with TBST then placed in a bath of TBST two times for 5 minutes each. Excess buffer was removed and samples were then incubated with Alexa Fluor 488 secondary antibody (Invitrogen A11029, A11008, Grand Island, NY) in a humidified chamber for 40 minutes. Following incubation, the slides were again rinsed twice in TBST bath for 5 minutes each. Excess buffer was removed, and cover slips were mounted using Dapi-Fluoromount-G (Southern Biotech, Birmingham, AL); slides were allowed to dry overnight. Samples were visualized using an Olympus IX70 fluorescence microscope (Olympus, Melville, NY).

Expression of BMP-6, EMMPRIN, and EGFR was assayed by scoring fluorescence intensity and distribution throughout the tissue samples. Fluorescence was scored independently and blindly by two investigators. Scores were assigned descriptively using an Allred scoring method, which was then modified by assigning a relative expression of 0 (low), 1 (mid-low), 2 (high-mid), or 3 (high) based on the distribution of scores among the biomarker in question\textsuperscript{15} (Fig. 1, Supplementary Fig. 1, Supplementary Fig. 2). Aggregated scores were then used for statistical analysis.

**Statistical Analyses**

Descriptive variables were summarized by mean (± standard deviation) for continuous variables and n (%) for categorical variables. A one-way analysis of variance was used to analyze relationships between categorical factors and continuous responses. A student t test was used to compare differences in means between groups. A contingency analysis was used to analyze relationships between categorical factors and responses. A multivariate analysis was performed to analyze the relationship between multiple variables. P < .05 was considered statistically significant. Statistical analysis was performed using JMP 10 software (SAS Institute Inc., Cary, NC).

**RESULTS**

**Patient Outcomes**

Thirty patients were included in this study and were separated into three cohorts based on their TAJCC/SIZE category. The first group represented small tumors of less than 4 cm that did not have bone invasion (T2/2), the second group represented small tumors that were upstaged based on bone invasion (T2/4), and the third group consisted of large tumors both with and without bone invasion (T4/4). The average follow-up time was 21 months (range, 9 days to 71 months). Patient demographics were not significantly different between any of the groups (Table I). At the conclusion of the study, 16 patients were deceased, with eight dying of their disease. Survival did not differ significantly between the three cohorts (Fig. 2). Age, race, and sex were not independent predictors of decreased survival. Patients with bone invasion and smaller tumors were more likely to undergo adjuvant radiation therapy (P = .03) than those with small tumors alone.

**Tumor Characteristics**

Tumor characteristics associated with a poorer prognosis and decreased survival have been well studied and include perineural invasion, lymphovascular invasion, margin status, invasion of surrounding structures, degree of squamous differentiation, and locoregional and distant metastasis.\textsuperscript{16} Interestingly, in this small cohort, metastatic disease, differentiation of the tumor, and upregulation of specific biomarkers were not associated with any decrease in survival. Furthermore, there was no significant impact on survival when looking at bone invasion between the three cohorts, although there was a trend toward decreased survival for the T2/4 cohort. Evidence of recurrent disease and perineural invasion were the only two tumor characteristics associated with significant decrease in survival (P = .019 and .007).

**Biomarkers**

Expression of BMP-6 was significantly higher in the smaller tumors with bone invasion (T2/4 cohort) compared to the larger tumors with bone invasion (T4/4 cohort, .019 and .007).
There was a nonsignificant increase in bony invasion in patients with increased expression of BMP-6 between the T2/2 and the T2/4 cohort, although it did trend toward significance. There was no increase in the incidence of perineural invasion, metastatic disease, or recurrence with increasing BMP-6 expression. When examining the relationship of BMP-6 to EGFR expression, we found an increased level of EGFR expression correlated with increased levels of BMP-6 ($P = .019$) (Fig. 4).

### TABLE I. Patient Demographics and Tumor Characteristics.

<table>
<thead>
<tr>
<th></th>
<th>T2/2% (n = 10)</th>
<th>T2/4% (n = 10)</th>
<th>T4/4% (n = 10)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td>.11</td>
</tr>
<tr>
<td>Male</td>
<td>50</td>
<td>80</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>50</td>
<td>20</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td>.40</td>
</tr>
<tr>
<td>White</td>
<td>90</td>
<td>90</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>10</td>
<td>10</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Bone invasion</td>
<td></td>
<td></td>
<td></td>
<td>.0001</td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>100</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>100</td>
<td>0</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Metastatic disease</td>
<td></td>
<td></td>
<td></td>
<td>1.00</td>
</tr>
<tr>
<td>Yes</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>80</td>
<td>80</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Perineural invasion</td>
<td></td>
<td></td>
<td></td>
<td>.38</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>10</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>90</td>
<td>90</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td></td>
<td></td>
<td></td>
<td>.86</td>
</tr>
<tr>
<td>Yes</td>
<td>30</td>
<td>30</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>70</td>
<td>70</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Margins positive</td>
<td></td>
<td></td>
<td></td>
<td>.24</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>40</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>90</td>
<td>60</td>
<td>60</td>
<td></td>
</tr>
</tbody>
</table>
Expression of EMMPRIN was not significantly different between the three cohorts. EMMPRIN expression had no correlation with perineural invasion or overall survival; although, there was a trend toward decreased survival with increased EMMPRIN expression. Higher expression levels of EMMPRIN were, however, associated with decreased incidence of metastatic disease ($P = .04$) as well as a trend toward decreased incidence of recurrence ($P = .06$). An increase in EMMPRIN expression trended toward a correlation with increased BMP-6 expression ($P = .20$).

Expression of EGFR was not significantly different between the three cohorts. There was no significant association between EGFR expression level and overall survival. However, increased EGFR expression did correlate with medullary invasion of bone versus cortical invasion. In addition, increased expression of EGFR significantly correlated with perineural invasion ($P = .01$) (Supplementary Fig. 3).

In patients who had bony invasion, higher EGFR scores were correlated with medullary invasion ($P = .03$). This was not seen with any of the other markers. When comparing the relationship between cortical and medullary bone invasion, there was no difference in overall survival.

**DISCUSSION**

This is the first study that examines the role of BMP-6 in the pathogenesis of bone invasion in oral cavity cancers. Using 30 tumor specimens of OCSCC, we examined the relationship between BMP-6 expression and bone invasion. This comparison was achieved by dividing tumors based on their AJCC staging as well as a classification based on size alone (TAJCC/SIZE). Several known biomarkers associated with poor prognosis of OCSCC were assessed in this investigation. In addition, standard predictors of poor prognosis were also examined in the context of biomarker expression. It was hypothesized that these standard predictors would correlate with the size-based and AJCC-based classification. In addition, expression of BMP-6 has previously been proven to correlate with bone invasion and found to be upregulated in squamous cell carcinoma of the esophagus. Given these relationships, we hypothesized it would also play a role in the invasive nature of OSCC and subsequently be a prognostic indicator. In this study, increased expression of BMP-6 was found to be associated with elevated EGFR expression levels, a known marker of poor prognosis.

In addition, in this study, EGFR expression was found to be associated with perineural invasion, a known predictor of significantly decreased overall survival. The relationship between perineural invasion and EGFR expression is still in its nascent phase in the otolaryngology literature, although this relationship has been shown in colorectal cancer. Given these relationships, it might be hypothesized that BMP-6 may be related to perineural invasion, although this was not captured in this small subset of patients.

Among the three groups, ($T_{2/2}$, $T_{3/4}$, $T_{4/4}$), there was no statistically significant difference in overall survival. Known predictors of poor prognosis (recurrence, perineural invasion, poor differentiation) showed a significant impact on overall survival, although metastatic disease and bone invasion did not. Our studies indicate that tumors that were small but also had aggressive phenotypes, including bone invasion, had increased expression of BMP-6 and had a prognosis similar to those patients with larger tumors, which confirms previous studies.

Given the well-studied relationship between bone invasion and prognosis, tumors with bone invasion in the oral cavity are automatically upstaged, regardless of size, in the current AJCC staging guideline. Our analysis found that those patients with small tumors and positive bone invasion exhibit a slightly poorer overall survival, although this was not found to be statistically significant. This finding is in support of the current AJCC staging criteria. Our data further suggest that the expression of BMP-6 may promote bone invasion.
With regard to survival, patients whose tumors demonstrated bone invasion on final pathologic specimen were more likely to undergo adjuvant therapy (70% vs. 20%, P = .03); this, too, is consistent with current guidelines. However, our data suggest that patients with small tumors and increased BMP-6 expression may benefit from more aggressive therapy, as they may be more predisposed toward invasive phenotypes. One of the three patients in the T2/2 cohort who also had high BMP-6 expression, but no bone invasion, developed metastatic disease as well as recurrence.

It has been shown that BMP-6 can not only be a marker for bony invasion, but also can be used as a possible prognostic indicator. In esophageal squamous cell carcinoma, Raida et al. showed that BMP-6 protein content is correlated with the grade of tumor-cell differentiation and may add to indications of poor prognosis. Molecular data have shown that BMP-6, when found in high levels and in conjunction with noggin and Sost in squamous cell carcinoma, can predict cancer progression. Importantly, this relationship was confirmed in prostate, bladder, and colorectal cancers.

CONCLUSION

Despite a limited sample size, this study suggests that there exists a potential correlation between BMP-6 and aggressive tumor phenotypes. Our data support the need for further investigation into the biological role of BMP-6 in bone invasion and metastasis in OCSCC. Predicting a tumor’s propensity for bone invasion is a useful tool for the head and neck surgeon as well as for the medical oncologist; expression levels of biomarkers may provide predictors toward more aggressive phenotypes requiring a more intensive treatment plan, as well as be a potential therapeutic target. Although only three biomarkers were investigated in this study, several interesting conclusions were found. These included the correlation between BMP-6 expression levels and more aggressive behaviors of the smaller lesions as well as increased EGFR expression. This study presents several interesting theories and highlights the need for additional research into the mechanisms associated with OCSCC bony invasion as well as the clinical correlation between these markers and clinical outcomes.

Acknowledgments

The authors wish to thank Yolanda Hartman, BS, and Taylor M. Deal, MD.

BIBLIOGRAPHY